Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American specialized coagulation laboratories

Kristi J. Smock, Elizabeth A. Plumhoff, Piet Meijer, Peihong Hsu, Nicole D Zantek, Nahla M. Heikal, Elizabeth M. Van Cott

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In 2010-2012, the North American Specialized Coagulation Laboratory Association (NASCOLA) distributed 12 proficiency testing challenges to evaluate laboratory testing for protein S (PS). Results were analysed to assess the performance of PS activity, PS free antigen, and PS total antigen testing. Statistical analysis was performed on the numeric results and qualitative classification submitted for each method. There were 2,106 total results: 716 results from PS activity assays, 833 results from PS free antigen assays, and 557 results from PS total antigen assays. The three assay types performed well in the classification of five normal samples and nine abnormal samples, although certain PS activity methods were more likely to classify normal samples as abnormal and one PS total antigen assay was more likely to classify abnormal samples as normal. PS activity methods were affected by interfering substances such as heterozygous or homozygous factor V Leiden mutation (underestimation) and the anticoagulant drug rivaroxaban (overestimation). In conclusion, NASCOLA laboratories using a variety of PS assays performed well in the classification of clearly normal and abnormal samples. Laboratories performing PS activity assays should be aware of potential interferences in samples positive for FV Leiden or containing certain anticoagulant medications.

Original languageEnglish (US)
Pages (from-to)50-57
Number of pages8
JournalThrombosis and Haemostasis
Volume116
Issue number1
DOIs
StatePublished - Jul 1 2016

Fingerprint

Protein S Deficiency
Protein S
Antigens
Anticoagulants
Rivaroxaban
factor V Leiden

Keywords

  • Direct oral anticoagulants
  • Factor V Leiden
  • NASCOLA
  • Proficiency testing
  • Protein S

Cite this

Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American specialized coagulation laboratories. / Smock, Kristi J.; Plumhoff, Elizabeth A.; Meijer, Piet; Hsu, Peihong; Zantek, Nicole D; Heikal, Nahla M.; Van Cott, Elizabeth M.

In: Thrombosis and Haemostasis, Vol. 116, No. 1, 01.07.2016, p. 50-57.

Research output: Contribution to journalArticle

Smock, Kristi J. ; Plumhoff, Elizabeth A. ; Meijer, Piet ; Hsu, Peihong ; Zantek, Nicole D ; Heikal, Nahla M. ; Van Cott, Elizabeth M. / Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American specialized coagulation laboratories. In: Thrombosis and Haemostasis. 2016 ; Vol. 116, No. 1. pp. 50-57.
@article{fff4a59f8a1646e596235e7e6548d6c7,
title = "Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American specialized coagulation laboratories",
abstract = "In 2010-2012, the North American Specialized Coagulation Laboratory Association (NASCOLA) distributed 12 proficiency testing challenges to evaluate laboratory testing for protein S (PS). Results were analysed to assess the performance of PS activity, PS free antigen, and PS total antigen testing. Statistical analysis was performed on the numeric results and qualitative classification submitted for each method. There were 2,106 total results: 716 results from PS activity assays, 833 results from PS free antigen assays, and 557 results from PS total antigen assays. The three assay types performed well in the classification of five normal samples and nine abnormal samples, although certain PS activity methods were more likely to classify normal samples as abnormal and one PS total antigen assay was more likely to classify abnormal samples as normal. PS activity methods were affected by interfering substances such as heterozygous or homozygous factor V Leiden mutation (underestimation) and the anticoagulant drug rivaroxaban (overestimation). In conclusion, NASCOLA laboratories using a variety of PS assays performed well in the classification of clearly normal and abnormal samples. Laboratories performing PS activity assays should be aware of potential interferences in samples positive for FV Leiden or containing certain anticoagulant medications.",
keywords = "Direct oral anticoagulants, Factor V Leiden, NASCOLA, Proficiency testing, Protein S",
author = "Smock, {Kristi J.} and Plumhoff, {Elizabeth A.} and Piet Meijer and Peihong Hsu and Zantek, {Nicole D} and Heikal, {Nahla M.} and {Van Cott}, {Elizabeth M.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1160/TH15-12-0918",
language = "English (US)",
volume = "116",
pages = "50--57",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "1",

}

TY - JOUR

T1 - Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American specialized coagulation laboratories

AU - Smock, Kristi J.

AU - Plumhoff, Elizabeth A.

AU - Meijer, Piet

AU - Hsu, Peihong

AU - Zantek, Nicole D

AU - Heikal, Nahla M.

AU - Van Cott, Elizabeth M.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - In 2010-2012, the North American Specialized Coagulation Laboratory Association (NASCOLA) distributed 12 proficiency testing challenges to evaluate laboratory testing for protein S (PS). Results were analysed to assess the performance of PS activity, PS free antigen, and PS total antigen testing. Statistical analysis was performed on the numeric results and qualitative classification submitted for each method. There were 2,106 total results: 716 results from PS activity assays, 833 results from PS free antigen assays, and 557 results from PS total antigen assays. The three assay types performed well in the classification of five normal samples and nine abnormal samples, although certain PS activity methods were more likely to classify normal samples as abnormal and one PS total antigen assay was more likely to classify abnormal samples as normal. PS activity methods were affected by interfering substances such as heterozygous or homozygous factor V Leiden mutation (underestimation) and the anticoagulant drug rivaroxaban (overestimation). In conclusion, NASCOLA laboratories using a variety of PS assays performed well in the classification of clearly normal and abnormal samples. Laboratories performing PS activity assays should be aware of potential interferences in samples positive for FV Leiden or containing certain anticoagulant medications.

AB - In 2010-2012, the North American Specialized Coagulation Laboratory Association (NASCOLA) distributed 12 proficiency testing challenges to evaluate laboratory testing for protein S (PS). Results were analysed to assess the performance of PS activity, PS free antigen, and PS total antigen testing. Statistical analysis was performed on the numeric results and qualitative classification submitted for each method. There were 2,106 total results: 716 results from PS activity assays, 833 results from PS free antigen assays, and 557 results from PS total antigen assays. The three assay types performed well in the classification of five normal samples and nine abnormal samples, although certain PS activity methods were more likely to classify normal samples as abnormal and one PS total antigen assay was more likely to classify abnormal samples as normal. PS activity methods were affected by interfering substances such as heterozygous or homozygous factor V Leiden mutation (underestimation) and the anticoagulant drug rivaroxaban (overestimation). In conclusion, NASCOLA laboratories using a variety of PS assays performed well in the classification of clearly normal and abnormal samples. Laboratories performing PS activity assays should be aware of potential interferences in samples positive for FV Leiden or containing certain anticoagulant medications.

KW - Direct oral anticoagulants

KW - Factor V Leiden

KW - NASCOLA

KW - Proficiency testing

KW - Protein S

UR - http://www.scopus.com/inward/record.url?scp=84977600784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977600784&partnerID=8YFLogxK

U2 - 10.1160/TH15-12-0918

DO - 10.1160/TH15-12-0918

M3 - Article

VL - 116

SP - 50

EP - 57

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 1

ER -